News Sentiment

INO sentiment intelligence

Inovio Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 46 Balanced news tone 66 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.18 Week of 10 Jul 2026
Weighted tone 46/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 13

high-authority source matches

Trend context Trend inactive

-3.3% over one week, +7.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

[EFFECT] INOVIO PHARMACEUTICALS, INC. SEC Filing

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -3.3% Price reacting lower
Trend fit Trend inactive 7.3% over four weeks
Fair value -73.0% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 47
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
MarketWatch 10
Stock Titan 7
Market source 6
TradingView 6
PR Newswire 4
TradingKey 3
simplywall.st 3
Ad Hoc News 3

Event Lens

What the news is about

Classified themes
Market update 39
Earnings 23
Regulatory and legal 2
Analyst action 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 66
Stock Titan Direct company coverage

[EFFECT] INOVIO PHARMACEUTICALS, INC. SEC Filing

This article reports on an SEC Filing (Form EFFECT) by INOVIO PHARMACEUTICALS, INC. (INO) which became effective on July 10, 2026, at 4:00 PM. The filing is a Notice of Effectiveness for an S-3 Shelf Registration. The article also provides an overview of INO's stock, recent news,

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 18:41
Source
Stock Titan
MarketWatch Direct company coverage

Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors

Shares of Inovio Pharmaceuticals Inc. (INO) fell 1.69% on Monday, closing at $1.16, while the broader market indexes, including the NASDAQ Composite and Dow Jones Industrial Average, also experienced declines. This marks the third consecutive day of losses for the stock.

Tone
Negative 29/100
Event
Market update
Published
13 Jul 2026 17:25
Source
MarketWatch
MarketWatch Direct company coverage

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Shares of Inovio Pharmaceuticals Inc. (INO) underperformed on Thursday, slipping 1.65% to $1.19 despite an overall positive trading session for the stock market. The NASDAQ Composite Index and Dow Jones Industrial Average both saw gains. The company's stock closed significantly b

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 17:22
Source
MarketWatch
AD HOC NEWS Direct company coverage

Inovio Pharmaceuticals updates investors on strategy as Nasdaq-listed biotech navigates a challengin

Inovio Pharmaceuticals, a Nasdaq-listed DNA medicine developer, is actively refining its clinical and funding strategy to advance its pipeline in infectious diseases and oncology. The company focuses on developing DNA medicines that stimulate the immune system and aims to create

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 14:09
Source
AD HOC NEWS
MarketWatch Direct company coverage

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Inovio Pharmaceuticals Inc. (INO) saw its stock rise by 4.31% to $1.21 on a challenging trading day when the NASDAQ Composite fell 1.16% and the Dow Jones Industrial Average fell 0.25%. Despite this outperformance, the company's stock closed significantly below its 52-week high.

Tone
Positive 70/100
Event
Market update
Published
07 Jul 2026 17:23
Source
MarketWatch
Finviz Direct company coverage

INO - Inovio Pharmaceuticals Inc Volatility & Greeks

This article provides a detailed statistical overview of Inovio Pharmaceuticals Inc (INO), including its current stock performance, financial health, and key ratios. It covers volatility metrics, Greek letters, insider and institutional ownership, and various performance indicato

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 15:40
Source
Finviz
Stock Titan Direct company coverage

Inovio Pharmaceuticals (NASDAQ: INO) files $300M shelf registration, notes BLA PDUFA

Inovio Pharmaceuticals has filed a shelf registration statement for up to $300 million in various securities, providing a flexible funding mechanism for the company. The filing highlights their lead candidate, INO-3107, an investigational DNA medicine for recurrent respiratory pa

Tone
Positive 64/100
Event
Regulatory and legal
Published
02 Jul 2026 19:39
Source
Stock Titan
MarketWatch Direct company coverage

Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains

Inovio Pharmaceuticals Inc. (INO) stock rose 2.52% to $1.22 on Thursday, marking its second consecutive day of gains. Despite this increase, the stock underperformed compared to its competitors during a mixed trading session, with the Dow Jones Industrial Average rising and the N

Tone
Negative 39/100
Event
Market update
Published
02 Jul 2026 17:21
Source
MarketWatch
MarketWatch Direct company coverage

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors

Shares of Inovio Pharmaceuticals Inc. (INO) fell 1.79% on Tuesday, closing at $1.10, despite a generally positive day for the broader stock market. The NASDAQ Composite Index and the Dow Jones Industrial Average both saw gains. This decline broke a two-day winning streak for Inov

Tone
Negative 29/100
Event
Market update
Published
30 Jun 2026 17:24
Source
MarketWatch
MarketWatch Direct company coverage

Inovio Pharmaceuticals Inc. stock rises Monday, still underperforms market

Inovio Pharmaceuticals Inc. (INO) saw its stock rise by 1.82% on Monday, closing at $1.12. Despite this gain, the stock underperformed the broader market, as the NASDAQ Composite and Dow Jones Industrial Average both saw larger increases. This marks the second consecutive day of

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 17:25
Source
MarketWatch
marketscreener.com Direct company coverage

Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) added to Russell Microcap Growth Benchmark Index

Inovio Pharmaceuticals, Inc. (NasdaqCM:INO) has been added to the Russell Microcap Growth Benchmark Index, an announcement made on June 28, 2026. This inclusion highlights the company's growth profile within the microcap segment. Inovio is a biotechnology firm focused on developi

Tone
Positive 66/100
Event
Market update
Published
28 Jun 2026 04:11
Source
marketscreener.com
TradingView Direct company coverage

Price to earnings forward of Inovio Pharmaceuticals, Inc. – NASDAQ:INO

This article provides financial information for Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Displaying the price to earnings forward, the content is situated within a broader financial data platform. It indicates the market status as closed with no current trades.

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 14:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Inovio Pharmaceuticals, Inc. – NASDAQ:INO

This article provides the "Price to sales forward" metric for Inovio Pharmaceuticals, Inc. (NASDAQ: INO). Displayed on the TradingView platform, it shows the current value and percentage change for this financial indicator. The information is presented within the context of marke

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 10:09
Source
TradingView
MarketWatch Direct company coverage

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains

Inovio Pharmaceuticals Inc. (INO) stock rose 1.85% on Friday, but still underperformed compared to the broader market indices like the NASDAQ Composite and Dow Jones Industrial Average, which experienced daily declines. Despite the gain, the stock ended a two-day losing streak.

Tone
Negative 39/100
Event
Market update
Published
26 Jun 2026 21:23
Source
MarketWatch
Simply Wall Street Direct company coverage

INO: Recent Equity Raises Will Set Up Future Repricing Potential

AnalystConsensusTarget has reduced its price target for Inovio Pharmaceuticals (INO) stock due to recent equity raises impacting the share count and valuation metrics. The fair value estimate has decreased by 24% to $5.83 per share, despite a higher future P/E multiple assumption

Tone
Negative 37/100
Event
Analyst action
Published
26 Jun 2026 12:40
Source
Simply Wall Street
TradingView Direct company coverage

Inovio Pharmaceuticals, Inc. Actuals & Estimates (BOATS:INO)

This article provides financial actuals and estimates for Inovio Pharmaceuticals, Inc. (BOATS:INO), including income statement, balance sheet, and cash flow data. It offers analyst forecasts with a maximum price target of $13.00 and a minimum of $1.80, and details past earnings,

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 23:40
Source
TradingView
TradingView Direct company coverage

INO Forecast — Price Target — Prediction for 2027

This article provides a forecast for Inovio Pharmaceuticals, Inc. (INO) stock, including analyst price targets, historical performance, and financial data. It covers earnings reports, revenue, net income, market capitalization, and volatility, along with FAQs about the stock.

Tone
Negative 28/100
Event
Earnings
Published
25 Jun 2026 23:40
Source
TradingView
TradingKey Direct company coverage

Inovio Pharmaceuticals Inc (INO) Institutional Confidence

Inovio Pharmaceuticals Inc (INO) currently holds an institutional shareholding score of 3.00, placing it 192nd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 40.31%, showing a 9.34% increase quarter-over-quarter. James Si

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 03:10
Source
TradingKey
MarketWatch Direct company coverage

Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Inovio Pharmaceuticals Inc. (INO) stock dropped 2.65% on Wednesday, closing at $1.10. This underperformance occurred on a mixed trading day, with the Dow Jones Industrial Average rising and the NASDAQ Composite Index falling. The company's stock is currently 63.07% below its 52-w

Tone
Negative 29/100
Event
Market update
Published
24 Jun 2026 17:23
Source
MarketWatch
TradingKey Direct company coverage

Inovio Pharmaceuticals Inc (INO) Valuation: PE, PB & Fair Value Analysis

Inovio Pharmaceuticals Inc (INO) currently holds a valuation score of 6.51, ranking 313 out of 389 in the Biotechnology & Medical Research industry as of June 23, 2026. The company's P/E ratio is -0.71, which is significantly below its recent high and above its recent low. Key va

Tone
Negative 39/100
Event
Market update
Published
23 Jun 2026 22:41
Source
TradingKey
MarketWatch Direct company coverage

Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains

Shares of Inovio Pharmaceuticals Inc. experienced a 1.80% gain on Tuesday, reaching $1.13, despite a general market downturn with the NASDAQ Composite and Dow Jones Industrial Average both falling. The company's stock closed significantly below its 52-week high of $2.98, achieved

Tone
Negative 35/100
Event
Market update
Published
23 Jun 2026 17:24
Source
MarketWatch
TradingKey Direct company coverage

Inovio Pharmaceuticals Inc (INO) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Inovio Pharmaceuticals Inc (INO), highlighting its current earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Based on 5 analysts, the average price target for INO is $8.00, with a consensus "Buy" r

Tone
Positive 75/100
Event
Earnings
Published
18 Jun 2026 10:10
Source
TradingKey
Moomoo Direct company coverage

Inovio Pharmaceuticals(INO) Stock Options Chain | Quotes & News

This article provides details about Inovio Pharmaceuticals (INO) stock, including its options chain, quotes, and related news. It serves as a resource for investors interested in tracking INO's market performance and derivative instruments. The content is designed to offer a quic

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 17:10
Source
Moomoo
GuruFocus Direct company coverage

Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript

This article provides the transcript of the Inovio Pharmaceuticals Inc Annual Shareholders Meeting held on May 20, 2026, at 01:00 PM GMT. The meeting, presided over by Chairman Simon Benito, was conducted through a virtual online platform. The document also lists various past ear

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 05:09
Source
GuruFocus
MarketWatch Direct company coverage

Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors

Inovio Pharmaceuticals Inc. (INO) stock dropped 7.76% to $1.07 on Friday, significantly underperforming broader market indices like the NASDAQ Composite and Dow Jones Industrial Average. The company's shares closed 64.08% below its 52-week high of $2.98.

Tone
Negative 18/100
Event
Market update
Published
05 Jun 2026 17:24
Source
MarketWatch
Morningstar Direct company coverage

Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for potential breaches of fiduciary duties by its officers and directors, following a federal securities lawsuit. The lawsuit alleges that the company misrepresented issues with its CELLECTRA device manuf

Tone
Negative 28/100
Event
Regulatory and legal
Published
05 Jun 2026 16:09
Source
Morningstar